ArticleClinical nephrology2017
Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study.
Article in Clinical nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A pharmacist-managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial.Pharmacology research & perspectives · 2020Trial
- Efficacy, safety, and dose selection of efepoetin alfa in anemic patients on maintenance dialysis: a phase 2, randomized, multicenter, active-controlled trial.Kidney research and clinical practice · 2026Article
- Exploring prognostic factors on vascular outcomes among maintenance dialysis patients and establishing a prognosis prediction model using machine learning methods.BMC medical informatics and decision making · 2025Article
- Usage of the Anemia Control Model Is Associated with Reduced Hospitalization Risk in Hemodialysis.Biomedicines · 2024Article
- Effects of Individualized Anemia Therapy on Hemoglobin Stability: A Randomized Controlled Pilot Trial in Patients on Hemodialysis.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- Contemporary Practice of Anemia Treatment Among Dialysis Patients in the United States.Kidney international reports · 2023Article
- Infectious Risk and Variability of Hemoglobin Level in Patients Undergoing Hemodialysis.Kidney international reports · 2023Article
- Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients.Kidney research and clinical practice · 2021Article
- Time-averaged hemoglobin values, not hemoglobin cycling, have an impact on outcomes in pediatric dialysis patients.Pediatric nephrology (Berlin, Germany) · 2018Article
- Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven regulatory and reimbursement changes in anemia management, we examined hemoglobin variability in a contemporary cohort of maintenance hemodialysis patients. MATERIALS AND
methodsThe study population included > 200,000 hemodialysis patients with Medicare parts A and B as primary payer on October 1, 2012. Based on 25th and 75th percentiles, monthly hemoglobin values were categorized as low, intermediate, or high. Six variability categories were created by patterns during the 6-month observation period. Stable categories were: always-low, alwaysintermediate, always-high; variable patterns were: varying between low and intermediate, intermediate and high, low and high (mostvariable). Cox proportional hazard models were used to assess the association between hemoglobin variability and all-cause mortality or major adverse cardiac events (MACE).
resultsThe 25
conclusionsIn 2012 vs. 2004, hemoglobin levels decreased, the range of levels narrowed, and variability decreased modestly; transfusions increased. The highest risk of mortality and MACE appeared to occur in patients with persistently low, rather than highly variable, hemoglobin levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.